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Abstract
Purpose: The aim of the present study was to gain insight into the penetration, biodistribution,
and fate of globulins in the brain after 2-O-hexyldiglycerol-induced blood–brain barrier opening.
Procedures: The spatial distribution of fluorescence probes was investigated after blood–brain
barrier opening with intracarotid 2-O-hexyldiglycerol injection. Fluorescence intensity was
visualized by microscopy (mice and rats) and by in vivo time-domain optical imaging.
Results: There was an increased 2-O-hexyldiglycerol-mediated transfer of fluorescence-labeled
globulins into the ipsilateral hemisphere. Sequential in vivo measurements revealed that the
increase in protein concentration lasted at least 96 h after administration. Ex vivo detection of
tissue fluorescence confirmed the results obtained in vivo.
Conclusion: Globulins enter the healthy brain in conjunction with 2-O-hexyldiglycerol. Sequential
in vivo near-infrared fluorescence measurements enable the visualization of the spatial
distribution of antibodies in the brain of living small animals.
Key words: BBB opening, 2-O-Hexyldiglycerol, Anti TGF-β antibody 1D11, Alexa Fluor 680,
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Introduction
T
reatment of brain disorders such as neurodegenerative
diseases or malignant brain tumors is still a major
problem. While there is progress in the development of
innovative chemical agents against brain disorders with
excellent results in vitro, the therapeutic use of enzymes or
antibodies in clinical settings is often limited [1, 2]. The
unsatisfactory transport of therapeutics to the brain tissue
results mostly from either low diffusion across the blood–
brain barrier (BBB) due to high molecular weight and/or low
lipophilicity or efflux mechanisms such as transporter
systems like P-glycoprotein, which carry substances from
the endothelium back into the brain capillary lumina [3, 4].
Several strategies have been described to increase the
tissue concentrations of drugs within the brain. One strategy
to open the BBB is the intracarotid infusion of hypertonic
mannitol [5] leading to shrinkage of the brain endothelial
cells and thereby widening cell–cell contacts [6]. Osmotic
BBB opening has already been successfully used to increase
the effectiveness of chemotherapy in animals and humans
with central nervous system tumors [7]. Other methods to
overcome the BBB with therapeutic intention are the use of
The article shows the possibility to visualize antibodies in the brain of mice
by near-infrared imaging after opening of the blood–brain barrier with 2-O-
hexyldiglycerol.
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istration as liposomal-coated nanoparticles [9], BBB opening
with bradykinin B2 receptor agonists like cereport (RMP-7,
Lobradimil) [10, 11], or the co-administration of P-glyco-
protein blocking drugs [12].
The intracarotid bolus administration of short chain
alkylglycerols has been reported to be a new effective and
well-controllable method to increase the transfer of even
larger drugs such as fluorescein isothiocyanate (FITC)–
Dextran 40000 and Lissamine–rhodamine B200 (RB200)
albumin to the ipsilateral hemisphere of healthy and brain
tumor bearing rats [13]. The opening of the BBB using 2-O-
hexyldiglycerol (HG) is short lasting, and almost no toxicity
has been described. Thirty minutes after intracarotid admin-
istration of HG, BBB integrity was shown to be restored
[14]. However, to date, there are no data available on the
alkylglycerol-mediated penetration of large 150-kDa-sized
drugs like enzymes or antibodies into the brain. Moreover,
no clear information exists about tissue distribution of large
drugs after entering the brain via the capillaries after the
BBB was permeabilized. In addition, there are no data
concerning the local distribution and the fate of large
molecules such as antibodies in the brain.
In view of the increasing possibilities in the field of
optical imaging, we could investigate the fate of fluorescent-
labeled proteins in vivo in the brain of small animals. Using
near-infrared fluorescent markers, we can measure tissue
penetration of the fluorescence probes [15, 16]. Time
domain in vivo optical imaging allows the simultaneous
analysis of both fluorescence intensity and fluorescence
lifetime, and also, tissue concentration of the markers could
be monitored [17]. For interpretation of the results, quanti-
tative in vivo imaging fluorescence detection was compared
with the evaluation by standard fluorescence microscopy.
Our results suggest that alkylglycerols are highly effica-
cious in carrying Cy 5.5 fluorescence labeled γ-globulins
(Cy 5.5 γ-globulin) or Alexa Fluor 680-coupled 1D11 anti-
TGF-β antibodies (Alexa Fluor 680 1D11 antibody) into the
brain of normal NMRI mice. The spatial distribution,
duration, and fate of the labeled antibodies are described
by near-infrared imaging of the brain over time in vivo.
Materials and Methods
Drugs
HG is a derivative of the alkylglycerol family with low systemic
toxicity. It was obtained from Genzyme Pharmaceuticals (Cam-
bridge, MA, USA) as a pure substance. For intraarterial admin-
istration, HG was diluted using sterile water and physiological
saline to iso-osmolar solutions to avoid osmotic effects. The
concentration used in our experiments was 82.5 mM HG.
Fluorescence markers of different molecular weight were
administered to visualize the permeability of the BBB in the
presence or absence of HG. Fluorescein sodium was used as low
molecular weight marker (MW 367 Da). It was purchased from
Merck (Darmstadt, Germany) and dissolved in physiological saline
to a 5% stock solution. A dose of 80 mg kg
−1 was given. For
intracarotid use, the stock solution was further diluted with
physiological saline to a total volume of 100 µl. RB200 and bovine
γ-globulin (150 kDa) were purchased from Sigma-Aldrich (Dei-
senhofen, Germany). Cy 5.5 was obtained from GE Healthcare Bio-
Sciences (Little Chalfont, UK). RB200 was coupled to γ-globulin
and purified as described by Klein et al. [18]. Cy 5.5 was also
coupled to γ-globulin according to the same protocol. The
concentration of RB200 γ-globulin was 80 mg ml
−1. For experi-
ments in mice, the solutions were given without further dilution,
whereas in rats, the dyes were further diluted 1:1 using physio-
logical saline. Alexa Fluor 680 1D11 antibody, a biological active
anti TGF-β antibody, was obtained from Genzyme Pharmaceuticals
(Cambridge, MA, USA). The concentration of the stock solution
was 1.2 mg ml
−1, and this marker was also used without further
dilution in mice experiments.
Animal Experiments
Male Wistar rats and male NMRI mice (Winkelmann, Borchen,
Germany) were used in combination with different fluorescence-
coupled agents (Table 1). In first short-time experiments with
microscopic evaluation of the success of BBB opening, rats were
used because the method was already established in our group. To
use the in vivo imaging system, the experiments had to be done in
mice. Thus, the animal was changed, and long-time analyses were
performed in mice. Animals were kept under conventional
controlled conditions (22°C, 55% humidity, and day–night rhythm)
and had free access to a standard diet (V1534-000, Fa. sniff, Soest,
Germany) and tap water. The experiments were performed in
accordance with the German Law on protection of animals.
Intraarterial Drug Administration
The animals were anesthetized by intraperitoneal ketamine/
xylazine. Wistar rats weighing 180–220 g received a dose of
90 mg kg
−1 body weight/7.5 mg kg
−1 body weight, and NMRI
mice weighing 37 to 45 g received a dose of 85 mg kg
−1 body
weight/7 mg kg
−1 body weight, respectively. For BBB opening
and drug administration, the right external carotid artery was
cannulated in a retrograde manner, using a self-made fine-glass
catheter. Branches of the external carotid artery were ligated. In
rats, a volume of 1,200 µl of HG (100 mM) was injected within
18 s using a Microlab M Hamilton dispenser (Microlab, Hamilton
Bonaduz, Switzerland). In mice, 300 µl of HG (100 mM for
microscopic evaluation and 82.5 mM for in vivo imaging) was
given within 18 s. Control animals received an equivalent
injection of physiological saline. Antegrade blood flow was
interrupted by clamping the common carotid artery during the
injection (18 s). In earlier experiments, a maximum penetration of
co-administered drugs to the brain was shown when given between 3
and 30 min after intracarotid injection of HG (75 mM; [14]).
Therefore, 5 min after the injection of HG, the fluorescent markers
weregivenasa10minshort-terminfusion(totalvolumeof1,000µlin
rats and of 100 µl in mice) using a fm Perfusor (Braun, Melsungen,
Germany). Thus, the amount given to mice was 8 mg of Cy 5.5 γ-
globulin and 120 µg of Alexa Fluor 680 1D11 antibody per animal.
After drug administration, the animals were euthanized (short-term
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was removed, and the animals were allowed to awake. At the end of
the experiments for fluorescence microscopy, the animals were
euthanized by intraperitoneal ketamine/xylazine overdose. The brain
was carefully removed and immediately frozen.
Microscopic Evaluation
For standard fluorescence microscopy, two different time points
were chosen for the evaluation of fluorescence intensity. In the first
experimental group, the brain was removed and shock frozen in
isopentane (−50°C) 10 min after the infusion of the marker
substances (short-term experiments). In the second group, animals
were allowed to awake, and the brains were removed and frozen
24 h after dye administration.
Frozen brains were cut in coronal slices of 7 µm using a Leica
cryotome CM 3050S, put on an ice-cold slide, and air-dried at −20°C
for1hbeforetheywerecarefullycoveredwithcoverslips,whichwere
stacked at the sides off the glass. Evaluation of the sections was
performed using fluorescence microscopy (Leica DM 5000B, Ger-
many). Fluorescein sodium was visualized using a FITC/Bodipy/
Fluo3/Dio filter cube. RB200 was evaluated using a Y3 filter cube.
PicturesweretakenusingaLeicaDC300FXcameraandanimage
analysis program (Leica FW4000). Exposure time was adjusted to the
fluorescence intensity of the tissue from the right hemisphere, where
the BBB was opened. Since in the left hemisphere the BBB was not
opened, thus, it was used as internal control.
In Vivo Imaging
To monitor the fate of the protein-bound near-infrared fluorescent
dyes within the brain tissue of treated mice, Alexa Fluor 680 and
Cy 5.5 were used. The fluorescent markers were visualized in the
time domain in vivo small animal fluorescence imager Optix™
(ART, Montreal, QC, Canada) [19, 20]. To evaluate the local
distribution of the fluorescent agents in the brain in vivo, the region
of the mouse brain was measured. Head-detector distance was
equal in all measurements. The system scans in a raster mode and a
step distance of 1 mm was selected in all experiments. For these
experiments, a 670-nm wavelength pulsed laser diode in combina-
tion with a 700-nm long pass filter was applied to the tissue, and
the laser power was optimized for each measurement (mean laser
power was 100 µW). For fluorescence detection, a time-correlated
single-photon counting system (TCSPC-130) was used. Since the
system is time-resolved, it is possible to provide fluorescence
lifetime in addition to intensity. This lifetime varies between
different chromophores and the fluorescence originating from the
animal tissue. Thus, lifetime measurement can be used to discrim-
inate between fluorescence originating from the dye administered to
the animal and auto-fluorescence [21].
Furthermore, the imaging system allows calculation of fluoro-
phore depth and concentration [22] as well as detection of
fluorescence from brain tissue deep under the skull [16]. Software
from Advanced Research technologies (ART, Montreal, QC,
Canada) was used for topographic representations of depth and
visualization of concentration and location within the animal profile
[23]. Intensity units were normalized for the same excitation power
and excitation time per raster point (integration time).
To reduce fluorescence absorbance and scattering of the coat,
the heads of the mice were epilated with cold wax stripes before the
first measurement. For all in vivo measurements, the mice were
anesthetized using inhalative isoflurane. Animals were placed in
prone position on the table of the imager. Anesthesia was maintained
duringthefluorescencedetectionbyofferinganoxygen-isofluranegas
mix via a small mask. Fluorescence measurement in the tissue was
performed repeatedly after BBB opening at defined time intervals up
to 96 h in order to describe the fate of the fluorescent markers within
this time. Two different control groups were evaluated in the same
manner: (1) mice treated with intracarotid fluorescent dyes without
BBB opening and (2) mice receiving HG without fluorescent markers
(physiological saline).
After the last in vivo imaging procedure, the animals were
euthanized, and the brains were removed from the skull. Immedi-
ately thereafter, fluorescence of the different brain areas was
remeasured in the Optix™ ex vivo. For this purpose, the brain
was dissected into the cerebellum, the right and the left hemisphere,
positioned in a Petri dish and covered with Tissue-Tec™ (Sakura
Finetek, Zoeterwoude, Netherlands) to prevent exsiccation. This
procedure was performed to distinguish fluorescence originating
from the brain and from extracerebral regions and to assign the
brain fluorescence to the different anatomical regions.
In Vitro Imaging
For in vitro calculation of fluorescence and fluorescence lifetime of the
protein-fluorochrome conjugates, 100 µl of tap water was applied onto
a1 - c m
2piece of filter paper in a Petri dish. On the paper, 10 µl of Alexa
Fluor 680 1D11 antibody diluted in NaCl 0.9% to a final concentration
of 29 µg/10 µl was used for the measurements in the Optix™.
Data Analysis
Fluorescence intensity data obtained by microscopy were calculated
using the Leica FW4000 image analysis program.
For in vivo imaging fluorescence intensity calculations, the
program Optix OptiView was used. Intensity units were normalized
for the same excitation power and excitation time per raster point
(integration time). Normalized fluorescence intensities are pre-
sented in arbitrary units. An area of 28 mm
2 (7 mm×4 mm)
approximately represents the region of one hemisphere of a mouse
Table 1. Fluorescence-coupled agents and the molecular weights and doses of each agent used in each animal
Fluorescent agent Dose Molecular weight Animals
Fluorescein sodium 80 mg kg
−1 ml
−1 367 Da Wistar rats
RB200 γ-globulin 80 mg animal
−1 ml
−1 ∼150 kDa Wistar rats
Alexa Fluor 680 1D11 antibody 120 µg animal
−1 0.1 ml
−1 ∼150 kDa NMRI mice
Cy 5.5 γ-globulin 8 mg animal
−1 ml
−1 ∼150 kDa NMRI mice
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2 area laid over the
hemisphere (ex vivo) or over the region of interest (in vivo) was
used for mean fluorescence intensity calculation in this regions.
For in vitro measurements and calculations, the region for
calculation of mean fluorescence was laid over the middle of the filter
paper. For lifetime calculations, the Levenberg–Marquard algorithm
was used. The concentration depth tool of the software was used to
calculate a three-dimensional distribution map of the fluorescence
concentration.Forthiscalculation,theabsorptioncoefficientwassetat
0.3 cm as it is in organic tissue and the scattering coefficient was set at
15 cm, which is expected in the brain.
Statistics were obtained with Sigma plot 3.5 software (Systat
Software Inc.) t tests (pG0.05) or Mann–Whitney rank sum tests.
Results
Microscopic Evaluation
Fluorescence in the brain of rats and mice was evaluated by
microscopy after administration of fluorescence-linked
agents in conjunction with intracarotid HG-mediated BBB
opening in the right hemisphere. The low molecular weight
fluorescent marker sodium fluorescein and the large marker
RB200 γ-globulin were given intravenously 5 min after
opening of the BBB by HG in rats. The intravenously
injected substances crossed the BBB and entered the brain
tissue of the hemisphere ipsilateral to the BBB opening
(Fig. 1). The increased intensity of RB200 fluorescence in
the HG-perfused brain regions indicates that significant
amounts of the large γ-globulins entered the brain of the
rats (Fig. 1b). To investigate the spatial distribution of the
fluorescence markers, serial sections of the brains were
analyzed. Tissue fluorescence was mainly increased in the
lateral cortex of the forebrain, indicating the highest level of
the permeabilizing effect of HG in this region. In the
contralateral left hemisphere, fluorescence was detectable
only within the lumina of the cerebral vessels, and no
extravasation of fluorescence was detected. The spatial
distribution of fluorescence obtained 10 min after BBB
opening resembled the pattern described in earlier experi-
ments using 1-O-pentylglycerol for BBB opening in con-
junction with the fluorescent markers fluorescein sodium
and RB200 albumin [14]. The fluorescence intensities
detected in the central nervous system of rats after intra-
carotid infusion of the fluorescent markers was higher than
in rats that received intravenous infusion of the markers
(data not shown). These results are in accordance with
earlier experiments using alkylglycerols and methotrexate
resulting in higher concentrations of methotrexate in the
brain when given as intracarotid infusion [14].
In mice, the markers were infused via the intracarotid
catheter 5 min after opening of the BBB. Tissue fluores-
cence was investigated 10 min (Fig. 2a, b) and 24 h after i.a.
administration of RB200 γ-globulin in mice (Fig. 2c, d).
After 24 h, ipsilateral tissue fluorescence was still signifi-
cantly increased compared with the contralateral hemisphere.
This shows that after initial extravasation, the protein marker
remained within the brain (Table 2). The intracarotid
injection of HG resulted in a strong increase in the transfer
of both sodium fluorescein and RB200 γ-globulin to the
ipsilateral brain tissue 10 min after BBB opening. Using
sodium fluorescein, a bright and almost homogeneous
staining in the ipsilateral brain was found 10 min after dye
administration (data not shown). In contrast to this, RB200
γ-globulin showed a patchy inhomogeneous distribution in
the brain tissue. Highest fluorescence was detected around
BBB-opened cerebral vessels (Fig. 2b). Images obtained
from animals euthanized 24 h after dye administration,
however, revealed a homogeneous staining of the marker
proteins reflecting a homogeneous distribution of the protein
within the brain tissue probably due to diffusion (Fig. 2d).
In Vivo Imaging
In order to describe the intraindividual behavior of large
markersinthebrainafterBBBopeninginvivo,wein ve st ig at ed
the intensity of globulin-coupled fluorescent dyes within the
Fig. 1. Spatial distribution of tissue fluorescence of fluorescein (a) and RB200 γ-globulin (b) in rat brain coronal sections after
BBB opening with 100 mM HG. The brain was removed 10 min after i.v. administration of the fluorescent markers. More
homogeneous tissue staining with the low molecular weight marker fluorescein as compared with RB200 γ-globulin. Right right
hemisphere, ipsilateral to the BBB opening procedure with HG; left left hemisphere, contralateral non-treated hemisphere.
Magnification 12.5-fold, bar=1 mm.
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was performed under short anesthesia at different time points
after treatment (up to 96 h). The fate of globulins was
visualized by in vivo near-infrared fluorescence imaging.
In the HG- and Cy 5.5 γ-globulin-treated animals, high
fluorescence intensities were detected in the right ipsilateral
hemisphere reflecting high tissue concentrations of Cy 5.5 γ-
globulin. Consistent with the results of microscopy,
increased fluorescence in the right hemisphere could be
detected after 9 h as well as 24 and 72 h after dye injection
(Fig. 3a). The fluorescence intensity in the right brain
seemed to increase within the first 9 h after BBB opening;
however, there was no statistical significance. Thereafter,
fluorescence intensity decreased slowly. Repeated measure-
ments after infusion of Cy 5.5 γ-globulin showed an
increased fluorescence signal in the right hemisphere up to
96 h in the HG-treated animals (Fig. 3b). In control animals
without Cy 5.5 γ-globulin administration, no fluorescence
was detected within the brain (Fig. 3b). After intracarotid
infusion of Cy 5.5 γ-globulin without barrier opening
(control 2), some brain tissue fluorescence was detectable.
This is in accordance with the results of microscopy,
showing intravascular fluorescence (Fig. 2). The fluores-
cence intensity in the right hemisphere was significantly
higher in HG-treated animals (pG0.05, t test), reflecting the
HG-mediated transfer of the marker across the BBB. At the
time point with maximum counts (after 9 h), the difference
to control 2 amounted to 52,400 normalized counts
(Fig. 3b). The fluorescence intensity ratio between right
and left hemispheres was significantly higher in HG and Cy
5.5 γ-globulin-treated compared with Cy 5.5 γ-globulin-
treated animals (t test: pG0.005 for the groups 24 and 96 h;
Mann–Whitney rank sum test: pG0.05 for the groups 3, 6, 9,
48, and 72 h) (Fig. 3c).
A signal depth reconstruction of the dye concentration in
the brain 6 h after treatment with HG localizes the
fluorescence signal 2 to 5 mm under the scull surface. This
equals the depth, where the brain tissue is located in the
mouse. In control experiments, low concentrations of the
fluorescent marker were found around the midline of the brain
(data not shown).
Ex Vivo Imaging
Specificity of the fluorescence signal was verified by both ex
vivo measurement of the fluorescence intensity within the
brain and in vivo detection of specific lifetime of Cy 5.5 γ-
Fig. 2. Time-dependent distribution of RB200 γ-globulin in the mouse brain after BBB opening with 100 mM HG. a Left
hemisphere, 10 min after intraarterial RB200 γ-globulin; b right hemisphere, 10 min after intraarterial RB200 γ-globulin; c left
hemisphere, 24 h after intraarterial RB200 γ-globulin; d right hemisphere, 24 h after intraarterial RB200 γ-globulin. The globulin
is diffusing from next to the capillaries and distributing equally throughout the hemisphere within 24 h. (Photographs were taken
under same conditions, magnification 200-fold, bar=0.05 mm).
Table 2. RB200 γ-globulin fluorescence intensity in the right and left
hemisphere 10 min and 24 h after BBB opening with HG
Time after dye administration Right Left
10 min 95.4±9.3 49.5±1.5
24 h 58.1
a±0.6 49.1
a±0.3
n=5 experiments
at test right vs left, pG0.001
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5.5 revealed a lifetime of 1.45 ns. There was a low auto-
fluorescence of the head of control animals with a lifetime of
0.51 ns (data not shown). These results proved that the
fluorescence signals in the brain detected by the optical
imaging system after BBB opening came from globulin-
coupled dyes.
To verify whether the fluorescence signal originated from
the brain tissue, we have performed ex vivo imaging of the
different brain regions after removing the brain. The highest
fluorescence intensities were found in the right hemisphere
of HG-treated mice as compared with controls 1 and 2
(Fig. 4). The right to left hemisphere ratio amounted to 3.65
after 9 h, 4.63 after 24 h, 5.75 after 72 h, and 3.62 after 96 h
(Fig. 4b). These were higher than the ratios calculated from
the in vivo data. The lifetime of the fluorescence detected
was specific to γ-globulin-coupled Cy 5.5 (not shown).
These data confirmed that the fluorescence detected by in
vivo imaging originated from Cy 5.5 in the brain tissue. The
ex vivo fluorescence intensity ratio gave evidence of a
slower decrease of Cy 5.5 γ-globulin concentration from the
right compared with the left hemisphere of the brain tissue
during the first 72 h after BBB opening.
Alexa Fluor 680 1D11 Imaging
In a second experimental series, a potentially biologically
active protein, Alexa Fluor 680 1D11 antibody, was used.
To evaluate the stability of the binding of 1D11 antibody to
the fluorochrome, the fluorescence intensity and lifetime of
the marker were investigated in vitro up to 72 h. There was
neither a decrease in fluorescence intensity nor a change of
the lifetime of the marker during the experimental period
(Fig. 5).
In vivo treatment of mice with Alexa Fluor 680 1D11
antibody (intracarotid infusion of 100 µl, 2 mg/ml) after
BBB opening with intracarotid HG (300 µl, 82.5 mM)
resulted in an increase in fluorescence intensity in the
ipsilateral right hemisphere (Fig. 6). The effect was
comparable with the experiments performed with Cy 5.5 γ-
globulin. The ex vivo evaluation of fluorescence intensity 6 h
after BBB opening showed a 1.9-fold higher fluorescence
intensity within the right hemisphere compared with the
non-treated left hemisphere (data not shown).
Discussion
The transfer, local distribution, and the fate of γ-globulins
within the brain of healthy rats and mice were investigated
after BBB opening with HG, a short chain alkylglycerol
derivative. HG causes a transient permeabilization of the
brain’s microvasculature [14]. Significant amounts of the
administered globulins were found in the right brain hemi-
sphere of healthy mice when administered after BBB
opening. Cy 5.5 γ-globulin was given at high doses (8 mg/
100 µl) to evaluate feasibility of in vivo optical imaging of
Fig. 3. Fluorescence of Cy 5.5 γ-globulin in the brain of mice measured by time-domain optical imaging. a In vivo fluorescence
i n t e n s i t yw i t h i nt h eb r a i no fc o n t r o l2a n d9h ,2 4ha n d7 2ha f t e rB B Bo p e n i n gw i t h8 2 . 5m MH Gf o l l o w e db yi . c .C y5 . 5γ-
globulin. Note the high intensity in the right (treated) hemisphere. b Time course of fluorescence intensity after the BBB opening
with 82.5 mM HG followed by intracarotid infusion of 8 mg Cy 5.5 γ-globulin. Fluorescence was measured over the right
hemisphere at different time points. The normalized counts represent average fluorescence intensity of a 28-mm
2 area located
over the right hemisphere. Dark blue BBB opening with 82.5 mM HG followed by i.c. infusion of Cy 5.5 γ-globulin (n=6). Green
control 1: BBB opening with 82.5 mM HG followed by intravenous infusion of physiological saline (n=6). Blue control 2:
intracarotid bolus of physiological saline followed by i.c. infusion of Cy 5.5 γ-globulin (n=2). c R i g h tt ol e f th e m i s p h e r e
fluorescence intensity ratio in control 1, control 2, and at different time points after BBB opening with 82.5 mM HG followed by
i.c. Cy 5.5 γ-globulin (pG0.05) for every time point compared with control 2.
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antibody, as a potentially therapeutic antibody, was infused
at putative therapeutic doses (0.12 mg/100 µl). The intra-
carotid infusion of the marker proteins in conjunction with
HG-mediated BBB opening resulted in a significant increase
in the delivery of both Cy 5.5 γ-globulin and Alexa Fluor
680 1D11 antibody to the ipsilateral brain of the mice. Thus,
Fig. 4. Ex vivo fluorescence of Cy 5.5 γ-globulin in the brain measured by time-domain optical imaging. a Imaging of the brain
24 h after treatment (r right hemisphere, l left hemisphere, c cerebellum). Control 1: HG + physiological saline. Low auto-
fluorescence. Control 2: intracarotid physiological saline plus 8 mg Cy 5.5 γ-globulin. Low fluorescence within all brain regions.
BBB opening with 82.5 mM HG and intracarotid infusion of 8 mg Cy 5.5 γ-globulin: highest intensity of Cy 5.5-mediated
fluorescence within the right hemisphere. b Fluorescence intensity at different time points after BBB opening with HG in the
right (red) and left hemisphere (blue). The counts represent normalized average fluorescence intensity of a 28-mm
2 area over
the right and left hemisphere, respectively. Control 1: BBB opening with HG followed by infusion of physiological saline. Control
2: intracarotid bolus injection of physiological saline followed by infusion of Cy 5.5 γ-globulin.
Fig. 5. Fluorescence intensity and lifetime of equal amounts
of Alexa Fluor 680 1D11 antibody. a Measurements were
performed using eXplore Optix TM in vitro 2 h and 48 h after
thawing. The solution was kept at room temperature between
the measurements. No change of lifetime under in vitro
conditions. b Time course of fluorescence intensity of 1D11
antibody in vitro. Fluorescence intensity of 0.2 mg/ml 1D11
antibody was measured using time-domain optical imaging
at different time points, n=6 independent experiments (t test:
p=0.329 between the groups 2 and 72 h).
Fig. 6. Normalized fluorescence intensity of Alexa Fluor 680
1D11 antibody in the brain in vivo.6( a), 9 (b), 24 (c), and 72 h
(d) after HG-mediated BBB opening.
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nervous system diseases using alkylglycerol-induced BBB
opening is feasible in an experimental mouse model.
The fluorescence was detectable as well in the brains in
vivo as in the dissected brains ex vivo. There was a high
interindividual variability in fluorescence intensity within
the ipsilateral right brain after HG treatment. Such variances
in brain penetration of co-administered drugs resulted from
the different extent of BBB opening by HG as described in
recent studies using alkylglycerols for BBB permeabilization
[13, 14]. Regarding the other brain regions, low Cy 5.5-
related fluorescence was found in the contralateral left
hemisphere and the cerebellum (Fig. 3a). In vivo, there was
a lower fluorescence intensity ratio between right and left
hemisphere than ex vivo. This phenomenon has recently also
been reported by others [24]. Reduction of the fluorescence
intensity by the scull between fluorescing dye in the brain
and detector can be a reason for this phenomenon.
Furthermore, there can be blooming from the right to the
left side of the brain. To prevent this, the ex vivo measure-
ments were performed after segmentation of the brains to
cerebellum, right and left hemisphere. To prevent differences
in fluorescence intensities between the brains due to differ-
ent perfusion quality, animals were not perfused. The lower
fluorescence intensity in the contralateral left hemisphere
shows that increased fluorescence intensity in the right
hemisphere cannot have its origin from the fluorescing agent
in the blood.
The analyses of fluorescence intensities of the marker
proteins within the first hours after drug administration
confirmed the data obtained from standard fluorescence
microscopy. A strong alkylglycerol-mediated penetration of
the labeled globulins was found in the treated (ipsilateral)
hemisphere. The microscopic images also showed that the
fluorescence detected by in vivo imaging originated from the
marker drugs within the brain tissue. Extravasation and brain
tissue staining by the labeled globulins was found by
conventional fluorescence microscopy and in vivo optical
imaging. High-resolution fluorescence microscopy yielded
additional information on the local distribution of the labeled
proteins in the different brain areas. Microscopy showed a
homogeneous distribution of the markers within the alkyl-
glycerol treated brain tissue 24 h after administration of the
dyes, whereas shortly after the injection, the antibodies were
found mainly around the capillaries. In contrast, small
molecules like sodium fluorescein showed a rapid and
homogeneous distribution in the brain tissue.
The integrity of the BBB can be effected by anesthetic
agents. In hyperosmolar BBB disruption, the effect of
various anesthetic agents was evaluated [25]. In contrast to
methoxyflurane or fentanyl-droperidol, ketamine/xylazine
anesthesia led to a good hyperosmolar-induced BBB
disruption. For our BBB opening procedure, ketamine/
xylazine was used. For alkylglycerols, the influence of the
anesthetic agent was not further investigated. Despite this, in
these experiments, a clip was applied to the common carotid
artery prior to HG infusion. It was shown by Fortin et al.
[26] that this procedure isolates the cerebral circulation from
the depressant hemodynamic effects of ketamine/xylazine.
Thus, the opening of the BBB is not effected by anesthesia.
In previous studies, it was shown that albumin enters the
brain tissue after co-administration with 1-O-pentylglycerol
[13]. However, compared with 1-O-pentylglycerol and other
short chain alkylglycerols, HG offers more favorable
pharmacodynamic properties, in particular a well-defined
time window for drug administration [14]. Using HG for
BBB opening, the drug of interest could be delivered as
short-term infusion several minutes after the permeabilizing
procedure [13]. This is of interest in view of both the use in
experimental animal models and the putative therapeutic use
for human diseases. Thus, the long-lasting HG-mediated
delivery of potentially therapeutic proteins in the present
study may offer new options in the treatment of brain
disorders.
In the HG-treated animals, elevated fluorescence of Cy
5.5 γ-globulin was detected within the ipsilateral brain
throughout the entire observation period up to 96 h.
Increased brain tissue fluorescence was also found up to
72 h after infusion of Alexa Fluor 680 1D11 antibody, which
was given at significantly lower doses (1.5% compared with
Cy 5.5 γ-globulin). In the past, γ-globulins have been shown
to enter the brain after osmotic BBB disruption using
hyperosmolar mannitol. In experiments using mannitol
25% and iodinated antibodies, I-125 radioactivity in the
brain increased during the first hour, remained high during
the next 23 h, and showed a rapid decline until 72 h post-
injection [27]. In dogs, co-injected Evans blue could be
f o u n di nt h eb r a i ne v e n5 2d a y sa f t e ro s m o t i cB B B
disruption [28]. This method was already successfully tested
in humans, but the use is restricted to a few clinics only.
Recently, sodium caprate has been reported to lead to a
reversible BBB opening in vitro [29] and in vivo [28].
However, after intracarotid infusion, severe brain edema was
seen at higher doses and a temporary hypertensive response
produced by intracarotid caprate infusion complicate the use
of sodium caprate as permeabilizing agent [30].
The near-infrared in vivo imaging system detects Cy 5.5
fluorescence. Alexa Fluor 680 has a comparable emission
spectrum as Cy 5.5 and can be detected using the same
analyzing system laser. Fluorescence intensity and fluores-
cence lifetime of Cy 5.5 γ-globulin and Alexa Fluor 680 1D11
antibody were sequentially evaluated in vivo by near-infrared
optical imaging in mice. Simultaneous detection of intensity
and lifetime at different time points after thawing showed that
the brain’s fluorescence measured in our experiments origi-
nated from the coupled dyes and that the fluorescence intensity
of the protein-coupled dye does not decrease over time.
However, fluorescence intensity cannot be compared between
theexperiments.Afterproteinbinding,theAlexaFluor680has
ah i g h e rf l u o r e s c e n c et h a nC y5 . 5[ 31].
In summary, HG was shown to offer new options for the
transport of proteins across the BBB into the central nervous
282 P. Hülper, et al.: Optical Imaging of Globulins after BBB Openingsystem, e.g., for the treatment of central nervous system
diseases with specific antibodies. In vivo near-infrared
fluorescence optical imaging is suited to visualize fluores-
cence of near-infrared fluorescence probes as Cy 5.5 and
Alexa Fluor 680 in the brain of mice after BBB opening.
Thus, the HG-mediated delivery of proteins into the brain in
conjunction with the use of optical imaging represents a new
and well-feasible experimental tool to investigate pharma-
cokinetics of therapeutic proteins in mice models with
central nervous system diseases.
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